Introduction {#S0001}
============

Breast cancer is the most frequent neoplasm and is leading major cause of cancer-related morbidity and mortality worldwide among women.[@CIT0001] In China, breast cancer has the highest incidence for females, and the incidence of breast cancer is increasing year after year.[@CIT0002] The postmenopausal women with breast cancer in China will reach 100/100,000 in the future, and the incidence of breast cancer is increasing rapidly in coastal developed cities of China.[@CIT0003] Although many patients with breast cancer are successfully treated by the early diagnoses and improved treatment strategies, approximately 20--25% patients are diagnosed with locally advanced breast cancer.[@CIT0004] Lots of studies have indicated that surgery combined with adjuvant chemoradiotherapy can effectively improve the survival rate of patients with breast cancer.[@CIT0005]--[@CIT0007]

Neoadjuvant chemotherapy (NACT) is the gold standard of care for locally advanced cancer and has been widely used to the treatment for locally advanced breast cancer.[@CIT0008] According to the NACT for breast cancer, the breast-conserving surgery rate is increasing, and the tumor stage is decreasing.[@CIT0009] Many NACT regimens have been applied to the treatment for breast cancer; however, there are no internationally generally accepted NACT regimens for patients with advanced breast carcinoma.[@CIT0010] Therefore, it is necessary to look for accurate and sensitive tumor indicators of breast cancer to improve the survival outcome and provide the better prognosis factor for breast cancer.

Some histologic and immunologic biomarkers have been used to evaluate the prognosis of breast cancer. However, these biomarkers largely depend on the primary tumor sample, and are often expensive, time-consuming and arduous, and are usually limited their use in clinical practice.[@CIT0011] The molecular subtypes, which include ER, PR, Ki-67, and HER2 expression condition, are very important for the prognosis of breast cancer. Hence, it is very important to search easily accessible and reliable markers for the prognosis of patients with breast cancer.

Cancer-related inflammation is a fundamental component of the tumor microenvironment and can influence the mechanism in the pathogenesis of patients with carcinoma. The inflammatory cells in peripheral venous blood might influence tumor carcinogenesis, progression, and metastasis.[@CIT0012] A great deal of studies have indicated that the inﬂammatory markers, such as white blood cell (W), neutrophil (N), monocyte (M), platelet (P), lymphocyte (L), as well as neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), are present and detectable in the systemic circulation, and have been widely proposed as prognostic factors for many malignancies.[@CIT0013]--[@CIT0016]

A novel and integrated indicator that named Systemic Inflammation Response Index (SIRI), which is based on neutrophil (N), monocyte (M), and lymphocyte (L) counts, is reported to be associated with clinical outcomes and predict the survival of patients with gastric cancer.[@CIT0017] This integrated indicator may comprehensively reflect the balance of host immune and inflammatory status compared with NLR, LMR, and PLR. Nevertheless, the SIRI has been studied rarely in breast cancer patients with treated NACT. Therefore, our study aims to evaluate the prognostic significance of SIRI in patients with breast cancer receiving NACT.

Materials and Methods {#S0002}
=====================

Study Population {#S0002-S2001}
----------------

We enrolled 262 patients with breast cancer undergoing NACT to this study in Cancer Hospital Chinese Academy of Medical Sciences from January 1999 to 2014 December. This research was a retrospective study. The detailed treatment information, clinical and demographic data for all enrolled patients were extracted from the medical record. This study was approved by the ethics committee of Cancer Hospital Chinese Academy of Medical Sciences. It complied with the standards of the Declaration of Helsinki and its later amendments. Written informed consent was obtained from all patients before the study.

The inclusion criteria for the patients were as follows: 1) all patients with breast cancer were confirmed by core needle biopsy before NACT treatment; 2) all patients received surgery treatment; 3) Karnofsky Performance Scores (KPS) ≥80 and Performance Status (Zubrod-ECOG-WHO, ZPS) ranged from 0 to 2 scores; 4) all patients had complete clinical records and follow-up information; 5) Patients could survive for more than 3 months; 6) the blood samples were obtained within 1 week before NACT treatment.

The exclusion criteria for the patients were as follows: 1) patients had received chemotherapy, radiotherapy, endocrine therapy, and targeted therapy before NACT treatment; 2) patients with malignant disease or distant metastases; 3) patients with serious complications, or any form of acute and chronic inflammatory disease; 4) patients who had blood product transfusion within 1 month before NACT treatment.

Chemotherapy Protocols {#S0002-S2002}
----------------------

We used anthracyclines-based and/or taxanes-based NACT regimens, and one cycle of these regimens was repeated every 3 weeks. Anthracyclines (Zhejiang Hisun Pharmaceutical Co., Ltd, Taizhou, China); Cyclophosphamide (Baxter Oncology GmbH, Halle, Germany); 5-Fluorouracil (Tianjin Jinyao Pharmaceutical Co., Ltd, China); Taxol (Jiangsu Hengrui Medicine Co., Ltd, Lianyungang, China); Platinum compounds (Bristol-Myers Squibb biopharmaceutical company, S.r.l., Italy).

AC regimen (A: 90 mg/m^2^, C: 600 mg/m^2^). ACF regimen (A: 90 mg/m^2^, C: 600 mg/m^2^, F: 500 mg/m^2^). CT regimen (C: 600 mg/m^2^, T: 175 mg/m^2^). ACT regimen (A: 90 mg/m^2^, C: 600 mg/m^2^, T: 175 mg/m^2^). AT regimen (A: 90 mg/m^2^, T: 175 mg/m^2^). TP regimen (T: 175 mg/m^2^, P: AUC 4--6).

Classification Standard and Response Evaluation {#S0002-S2003}
-----------------------------------------------

We used the eighth edition of American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) TNM stage classification to evaluate the tumor pathology stage of all enrolled patients.[@CIT0018],[@CIT0019] Breast cancer molecular subtypes were classified as Luminal A, Luminal B HER2-positive, Luminal B HER2-negative, HER2-enriched, and triple negative.[@CIT0020] The Miller and Payne grade (MPG) was used to determine the histological response.[@CIT0021] Response rates were defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.[@CIT0022] The hematoxylin and eosin (HE) stain was used to diagnose lymph vessel invasion and neural invasion of tumor. The National Cancer Institute Common Toxicity Criteria (NCICTC) was used to evaluate the toxicity of NACT.

Peripheral Venous Blood Parameters {#S0002-S2004}
----------------------------------

Peripheral venous blood samples were obtained within 1 week before NACT. The samples were collected by a sterile EDTA tube and obtained with empty stomach. Hematologic parameters were analyzed by XE-2100 hematology analyzer (Sysmex, Kobe, Japan).

Follow-Up {#S0002-S2005}
---------

All patients were followed up by inpatients and outpatients every 3 months for the first to second year after surgery, every 6 months for the third to fifth year after surgery, then annually every year and until death.[@CIT0023] Follow-up assessments included laboratory tests (routine blood test, blood biochemical), breast ultrasonography, mammography and some other examinations as it fits. Disease-free survival (DFS) was defined as the time from the date of surgery to the date of local recurrence or distant metastases, death from any cause or last follow-up. Overall survival (OS) was defined as the time from the date of surgery to the date of death from any cause or last follow-up.

Statistical Analysis {#S0002-S2006}
--------------------

The optimal cutoff value was accessed by the receiver operating characteristic curve (ROC) analyses, and the area under the curve was determined by the predictive value. The ratio closest to the point with maximum sensitivity and specificity was defined as the optimal cutoff value. The clinicopathologic categorical variables were presented as frequencies and percentages (%), and the associations between breast cancer and clinicopathological variables were evaluated using the chi-square test or Fisher's exact test. The association between breast cancer and survival was analyzed by the Kaplan--Meier plots and log-rank test. The independent prognostic factors were accessed by the univariate and multivariate Cox proportional hazards regression model, and the hazard ratios (HRs) and 95% confidence interval (CI) were obtained by the Cox proportional hazards regression model. All statistical analyses were performed using the SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA) and GraphPad prism software (version 5.0; GraphPad Inc., La Jolla, CA, USA). Alpha was set at 0.05, and a two-tailed P\<0.05 was considered statistically significant.

Results {#S0003}
=======

Demographic and Clinicopathologic Characteristics of All Breast Cancer Patients {#S0003-S2001}
-------------------------------------------------------------------------------

We enrolled 262 cases with breast cancer in this retrospective study. The optimal cutoff value of SIRI by ROC analysis was 0.85×10^9^/L, and the optimal cutoff value was used for all analyses. The patients with breast cancer were categorized into two groups by SIRI: low SIRI group (\<0.85×10^9^/L) and high SIRI group (≥0.85×10^9^/L). The clinicopathological characteristics of patients with breast cancer were shown in [Table 1](#T0001){ref-type="table"}. All enrolled patients were females. The age was ranged from 27 to 73 years, and the median age was 48 years. In low SIRI group, there were 155 patients (59.2%), and in high SIRI group, there were 107 patients (40.8%). The median body mass index (BMI) of all patients was ranged from 18.03 to 39.06, and the median BMI was 24.50. In this study, a low SIRI was significantly associated with menopause (*χ*^2^=3.895, P=0.048), US-LNM (*χ*^2^=4.975, P=0.026), total lymph nodes (*χ*^2^=4.065, P=0.044).Table 1Demographic and Clinicopathologic Characteristics of All Breast Cancer PatientsParametersLow SIRI＜0.85High SIRI≥0.85*χ*^2^P valueCases (n)262155 (59.2%)107 (40.8%)Age (years)0.8400.359 ＜48138 (52.7%)7860 ≥48124 (47.3%)7747Marital status0.9150.922 Married243 (92.7%)14598 Unmarried9 (3.4%)54 Divorce7 (2.7%)43 Widowhood3 (1.2%)12Occupation0.8260.662 Mental worker165 (63.0%)10164 Manual worker35 (13.4%)2015 Others62 (23.6%)3428BMI0.0200.888 ＜24.50148 (56.5%)8761 ≥24.50114 (43.5%)6846Menopause3.8950.048 No160 (61.1%)8773 Yes102 (38.9%)6834ABO blood type2.4860.647 A84 (32.1%)5232 B78 (29.7%)4434 O73 (27.9%)4033 AB27 (20.3%)198Tumor site0.3820.536 Right126 (48.1%)7749 Left136 (51.9%)7858Primary tumor site2.0020.735 Upper outer quadrant166 (63.4%)9571 Lower outer quadrant21 (8.0%)147 Lower inner quadrant12 (4.6%)84 Upper inner quadrant38 (14.5%)2513 Central25 (9.5%)1312US-Tumor size0.3440.842 ≤2cm95 (36.3%)5837 ＞2 and ＜5cm138 (52.6%)8157 ≥5cm29 (11.1%)1613US-LNM4.9750.026 No156 (59.5%)10155 Yes106 (40.5%)5452US-BIRADS classification1.3600.506 436 (13.8%)1917 5103 (39.3%)5944 6123 (46.9%)7746Clinical stageClinical T stage2.6950.610 T147 (17.9%)2819 T2117 (44.7%)7542 T366 (25.2%)3531 T432 (12.2%)1715Clinical N stage1.4430.837 N048 (18.3%)3117 N189 (34.0%)4940 N277 (29.4%)4532 N348 (18.3%)3018Clinical TNM stage0.1890.664 II107 (40.8%)6542 III155 (59.2%)9065Type of surgery0.0080.930 Mastectomy221 (84.4%)13190 Breast-conserving surgery41 (15.6%)2417Tumor size3.5440.170 ≤2cm117 (44.7%)6255 ＞2 and ＜5cm120 (45.8%)7842 ≥5cm25 (9.5%)1510Histologic type2.3720.305 Ductal251 (95.8%)149102 Lobular4 (1.5%)13 Others7 (2.7%)52Histologic grade3.6260.163 I74 (28.2%)3737 II136 (51.9%)8650 III52 (19.9%)3220Pathological TNM classificationPathological T stage1.9120.752 Tis/T042 (16.0%)2220 T1101 (38.6%)5942 T282 (31.3%)5131 T325 (9.5%)178 T412 (4.6%)66Pathological N stage0.3610.986 N098 (37.4%)5741 N151 (19.5%)3120 N240 (15.3%)2515 N373 (27.8%)4231Pathological TNM stage1.6620.798Tis/T034 (13.0%)1915 I47 (17.9%)2621 II59 (22.5%)3920 III122 (46.6%)7151Total lymph nodes4.0650.044 ＜21120 (45.8%)6357 ≥21142 (54.2%)9250Positive lymph nodes0.1500.928 097 (37.0%)5740 ＜671 (27.1%)4130 ≥694 (35.9%)5737Total axillary lymph nodes0.9260.336 ＜20118 (45.0%)6652 ≥20144 (55.0%)8955Positive axillary lymph nodes0.0480.976 099 (37.8%)5841 ＜563 (24.1%)3726 ≥5100 (38.1%)6040Postoperative complications0.2170.641 No253 (96.6%)149104 Yes9 (3.4%)63Postoperative radiotherapy0.3230.570 No61 (23.3%)3823 Yes201 (76.7%)11784Postoperative endocrine therapy0.0520.819 No130 (49.6%)7654 Yes132 (50.4%)7953Postoperative targeted therapy1.3780.240 No189 (72.1%)11673 Yes73 (27.9%)3934

Relationships Between SIRI and Hematologic Parameters {#S0003-S2002}
-----------------------------------------------------

In this study, the maximum (sensitivity + specificity) point of the ROC curve was regarded as the optimal cutoff value of SIRI. The cutoff value of ALT, AST, LDH, IgA, IgG, IgM, ALB, CRP, CA125, CA153, CEA, D-D, FDP, W, R, Hb, N, M, P, L, NLR, MLR, PLR by median value were 23 U/L, 23 U/L, 190 U/L, 2.30 g/L, 11.67 g/L, 1.27 g/L, 44.00 g/L, 1.10 mg/dl, 27.73 U/mL, 21.86 U/mL, 3.52 ng/mL, 0.83 mg/L FEU, 2.01 ug/mL, 6.00×10^9^/L, 4.34×10^9^/L, 128.00×10^9^/L, 3.83×10^9^/L, 1.67×10^9^/L, 0.34×10^9^/L, 244.00×10^9^/L, 2.50, 0.22, 160.00, respectively. The hematologic parameters of patients with breast cancer are shown in [Table 2](#T0002){ref-type="table"}. A low SIRI was significantly related to W (*P*\<0.001), Hb (*P*=0.010), N (*P*\<0.001), L (*P*=0.030), M (*P*\<0.001), NLR (*P*\<0.001), MLR (*P*\<0.001), PLR (*P*=0.003) ([Table 2](#T0002){ref-type="table"}).Table 2Relationships Between SIRI and Hematologic ParametersParametersLow SIRI＜0.85High SIRI≥0.85*χ*^2^P valueCases (n)262155 (59.2%)107 (40.8%)ALT0.0050.943 ＜23183 (69.9%)10875 ≥2379 (30.1%)4732AST0.5310.466 ＜23182 (69.5%)10577 ≥2380 (30.5%)5030LDH0.0800.778 ＜190174 (66.4%)10470 ≥19088 (33.6%)5137IgA0.0190.892 ＜2.30136 (51.9%)8155 ≥2.30126 (48.1%)7452IgG0.8160.366 ＜11.67141 (53.8%)8754 ≥11.67121 (46.2%)6853IgM0.7430.389 ＜1.27160 (61.1%)9862 ≥1.27102 (38.9%)5745ALB0.0710.790 ＜44.0098 (37.4%)5939 ≥44.00164 (62.6%)9668CRP0.9730.323 ＜1.10226 (86.3%)13195 ≥1.1036 (13.7%)2412CA1250.7840.376 ＜27.73224 (85.5%)13589 ≥27.7338 (14.5%)2018CA1530.5420.461 ＜21.86209 (79.8%)12683 ≥21.8653 (20.2%)2924CEA0.4750.491 ＜3.52211 (80.5%)12784 ≥3.5251 (19.5%)2823D-D0.1060.744 ＜0.83218 (83.2%)12890 ≥0.8344 (16.8%)2717FDP0.0050.941 ＜2.01156 (59.5%)9264 ≥2.01106 (40.5%)6343White blood cell (W)28.720＜0.001 ＜6.00133 (50.8%)10033 ≥6.00129 (49.2%)5574Red blood cell (R)1.2250.268 ＜4.34116 (44.3%)7343 ≥4.34146 (55.7%)8264Hemoglobin (Hb)6.6600.010 ＜128.00108 (41.2%)7434 ≥128.00154 (58.8%)8173Neutrophil (N)67.708＜0.001 ＜3.83134 (51.2%)11222 ≥3.83128 (48.8%)4385Lymphocyte (L)4.7120.030 ＜1.67143 (54.6%)7667 ≥1.67119 (45.4%)7940Monocyte (M)58.091＜0.001 ＜0.34133 (50.8%)10924 ≥0.34129 (49.2%)4683Platelet (P)0.4090.523 ＜244.00136 (51.9%)8353 ≥244.00126 (48.1%)7254NLR92.661＜0.001 ＜2.50160 (61.1%)13228 ≥2.50102 (38.9%)2379MLR99.033＜0.001 ＜0.22152 (58.0%)12923 ≥0.22110 (42.0%)2684PLR8.7680.003 ＜160.00158 (60.3%)10553 ≥160.00104 (39.7%)5054

Association of SIRI and NACT or Postoperative Chemotherapy {#S0003-S2003}
----------------------------------------------------------

All enrolled patients received anthracyclines-based and taxanes-based NACT regimens. All cases were treated with NACT, and 27 patients received the AC/ACF regimen, 29 patients received the CT/ACT regimen, 121 patients received the AT regimen, 75 patients received TP regimen, and 10 patients received other regimens, such as FP, T, F, TF, EV regimen. However, 116 patients were received postoperative chemotherapy, and 18 patients were treated with AC/ACF regimen, 17 patients were treated with CT/ACT regimen, 27 patients were treated with AT regimen, 21 patients were treated with TP regimen, and 33 patients were treated with other regimens, such as C, CTF, CTP, A, AF, AMF, AP, F, FP, T, TF, V, VP regimen. The clinical objective response rate (CR+PR) was 61.4%, and the clinical benefit rate (CR+PR+SD) was 97.3%, and non-clinical response rate (SD+PD) was 38.6%. The pathological response was accessed by MPG system, and the grade 1 rate was 5.0%, the grade 2 rate was 29.8%, the grade 3 rate was 39.3%, the grade 4 rate was 10.3%, and the grade 5 rate was 15.6%. Moreover, the pathological response of pCR rate was 20.6%. The NACT or postoperative chemotherapy of patients with breast cancer is shown in [Table 3](#T0003){ref-type="table"}. A low SIRI was significantly related to NACT (*P*=0.004).Table 3Association of SIRI and Neoadjuvant Chemotherapy or Postoperative ChemotherapyParametersLow SIRI＜0.85High SIRI≥0.85*χ*^2^P valueCases (n)262155 (59.2%)107 (40.8%)Neoadjuvant chemotherapy regimen15.2690.004 AC/ACF27 (10.3%)1710 CT/ACT29 (11.1%)227 AT121 (46.2%)7843 TP75 (28.6%)3144 Others10 (3.8%)73Chemotherapy times0.5310.466 ＜685 (32.4%)5332 ≥6177 (67.6%)10275Response2.1050.716 CR5 (1.9%)32 PR156 (59.5%)9165 SD94 (35.9%)5539 PD7 (2.7%)61Miller and Payne grade4.2520.373 113 (5.0%)76 278 (29.8%)5028 3103 (39.3%)6439 427 (10.3%)1215 541 (15.6%)2219Pathological response0.3660.545 pCR54 (20.6%)3024 Non-pCR208 (79.4%)12583Postoperative chemtherapy regimen1.6180.899 0146 (55.7%)8561 AC/ACF18 (6.9%)99 CT/ACT17 (6.5%)107 AT27 (10.3%)189 TP21 (8.0%)129 Others33 (12.6%)2112Postoperative chemotherapy times1.2940.523 0146 (55.7%)8561 ＜441 (15.7%)2219 ≥475 (28.6%)4827

Correlation Between SIRI and Breast Cancer Molecular Subtypes {#S0003-S2004}
-------------------------------------------------------------

All enrolled cases were diagnosed and confirmed by core needle biopsy prior to NACT. Before NACT, 8 cases were Luminal A subtype, 27 cases were Luminal B HER2-positive subtype, 98 cases were Luminal B HER2-negative subtype, 62 cases were HER2-enriched subtype, and 67 cases were triple-negative subtype, respectively. After NACT and surgery, 9 patients were Luminal A subtype, 25 patients were Luminal B HER2-positive subtype, 94 patients were Luminal B HER2-negative subtype, 66 patients were HER2-enriched subtype, and 68 patients were triple-negative subtype, respectively. There was no significant association between tumor molecular subtypes and SIRI ([Table 4](#T0004){ref-type="table"}).Table 4Correlation Between SIRI and Breast Cancer Molecular SubtypesParametersLow SIRI＜0.85High SIRI≥0.85*χ*^2^P valueCases (n)262155 (59.2%)105 (40.8%)Core needle biopsyMolecular subtype2.8110.590 Luminal A8 (3.1%)53 Luminal B HER2+27 (10.3%)1413 Luminal B HER2-98 (37.4%)6434 HER2 enriched62 (23.7%)3428 Triple negative67 (25.5%)3829ER status0.9880.320 Negative108 (41.2%)6048 Positive154 (58.8%)9559PR status0.8570.354 Negative129 (49.2%)8049 Positive133 (50.8%)7558HER2 status0.4680.494 Negative (0\--++)168 (64.1%)10266 Positive (+++)94 (35.9%)5341Ki-67 status0.0220.882 Negative (≤14%)60 (22.9%)3525 Positive (＞14%)202 (77.1%)12082Postoperative pathology (IHC)Molecular subtype1.8820.758 Luminal A9 (3.4%)63 Luminal B HER2+25 (9.5%)1411 Luminal B HER2-94 (35.9%)5935 HER2 enriched66 (25.2%)3531 Triple negative68 (26.0%)4127ER status0.0880.767 Negative122 (46.6%)7151 Positive140 (53.4%)8456PR status0.0160.900 Negative131 (50.0%)7853 Positive131 (50.0%)7754HER2 status0.9400.332 Negative (0\--++)173 (66.0%)10667 Positive (+++)89 (34.0%)4940Ki-67 status0.4090.523 Negative (≤14%)92 (35.1%)5240 Positive (＞14%)170 (64.9%)10367AR status0.0710.790 Negative164 (62.6%)9668 Positive98 (37.4%)5939CK5/6 status1.3570.244 Negative228 (87.0%)13890 Positive34 (13.0%)1717E-cad status0.4110.521 Negative109 (41.6%)6742 Positive153 (58.4%)8865EGFR status0.1110.739 Negative198 (75.6%)11682 Positive64 (24.4%)3925P53 status0.0750.784 Negative132 (50.4%)7755 Positive130 (49.6%)7852TOP2A status1.8380.175 Negative107 (40.8%)5849 Positive155 (59.2%)9758Lymph vessel invasion0.2270.634 Negative162 (61.8%)9468 Positive100 (38.2%)6139Neural invasion2.6050.107 Negative197 (75.2%)11186 Positive65 (24.8%)4421

Correlation Between SIRI and Side Effects of Chemotherapy {#S0003-S2005}
---------------------------------------------------------

In this study, the common toxicities after NACT were hematologic and gastrointestinal reaction. And we used the NCICTC to evaluate and analyze the side effects of NACT. There were no chemotherapy-related deaths in our study. Moreover, we used the SIRI to access the side effects of NACT, and the result indicated that the SIRI before NACT had no significance on toxicities of all enrolled patients, excepted diarrhea (*χ*^2^=4.199, *P*=0.040) ([Table 5](#T0005){ref-type="table"}).Table 5Main Toxicities According to NCICTC Scale of the Patients with Breast Cancer Undergoing Neoadjuvant ChemotherapyParametersLow SIRI＜0.85High SIRI≥0.85*χ*^2^P valueCases (n)262155 (59.2%)107 (40.8%)Decreased appetite0.1550.694 No20 (7.6%)119 Yes242 (92.4%)14498Nausea0.1610.688 No14 (5.3%)95 Yes248 (94.7%)146102Vomiting0.5980.439 No98 (37.4%)5543 Yes164 (62.6%)10064Diarrhea4.1990.040 No237 (90.5%)14592 Yes25 (9.5%)1015Mouth ulcers3.1130.078 No252 (96.2%)147105 Yes10 (3.8%)82Alopecia0.1150.735 No111 (42.4%)6744 Yes151 (57.6%)8863Peripheral neurotoxicity0.3830.536 No239 (91.2%)14099 Yes23 (8.8%)158Anemia0.6610.718 Grade 098 (37.4%)6137 Grade 1--2162 (61.8%)9369 Grade 3--42 (0.8%)11Leukopenia0.2300.891 Grade 077 (29.4%)4730 Grade 1--2106 (40.5%)6145 Grade 3--479 (30.1%)4732Neutropenia1.3650.505 Grade 072 (27.5%)4527 Grade 1--2104 (39.7%)5747 Grade 3--486 (32.8%)5333Thrombocytopenia1.0890.580 Grade 0178 (67.9%)10474 Grade 1--281 (30.9%)5031 Grade 3--43 (1.2%)12Gastrointestinal reaction0.1190.942 Grade 09 (3.4%)54 Grade 1--2250 (95.4%)148102 Grade 3--43 (1.2%)21Myelosuppression0.2900.865 Grade 055 (21.0%)3421 Grade 1--2101 (38.5%)5843 Grade 3--4106 (40.5%)6343

Univariate and Multivariate Cox Regression Survival Analyses {#S0003-S2006}
------------------------------------------------------------

We used the univariate and multivariate Cox proportional-hazards models to determine the independent prognostic factors. According to univariate and multivariate analysis, the clinical T stage, Miller and Payne grade, pathological T stage, pathological TNM stage, core needle biopsy (molecular subtype, ER status, Ki-67 status), postoperative pathology IHC (Ki-67 status), neural invasion, PLR, SIRI, postoperative chemotherapy, postoperative radiotherapy for DFS and OS were the significant prognostic factors ([Table 6](#T0006){ref-type="table"}). The median DFS and OS of all enrolled patients were 36.85 months (range from 4.00 to 197.97 months) and 49.95 months (range from 5.93 to 250.97 months), respectively ([Figure 1A](#F0001){ref-type="fig"} and [B](#F0001){ref-type="fig"}).Table 6Univariate and Multivariate Cox Regression Survival Analyses of the SIRI for the Prediction of DFS and OS in Breast Cancer PatientsParametersDFSOSUnivariate AnalysisMultivariate AnalysisUnivariate AnalysisMultivariate AnalysisHazard Ratio (95% CI)P valueHazard Ratio (95% CI)P valueHazard Ratio (95% CI)P valueHazard Ratio (95% CI)P valueAge (years)0.0580.093 ＜481 (Reference)1 (Reference) ≥484.013 (0.955--16.870)3.857 (0.800--18.597)BMI0.470.237 ＜24.501 (Reference)1 (Reference) ≥24.502.352 (1.012--5.463)1.564 (0.218--3.457)Menopause0.7370.278 No1 (Reference)1 (Reference) Yes0.765 (0.159--3.670)0.394 (0.073--2.123)ABO blood type0.0540.0290.033 A1 (Reference)1 (Reference)1 (Reference) B1.772 (0.463--6.787)2.936 (0.860--10.021)1.913 (1.008--3.632) O4.277 (1.317--13.890)7.667 (2.024--29.049)2.666 (1.323--5.370) AB1.109 (0.182--6.754)4.403 (0.621--31.223)2.402 (1.018--5.665)Primary tumor site0.1320.595 Upper outer quadrant1 (Reference)1 (Reference) Lower outer quadrant0.539 (0.093--3.122)1.285 (0.208--7.944) Lower inner quadrant1.389 (0.576--3.566)0.241 (0.004--12.903) Upper inner quadrant0.483 (0.131--1.777)0.300 (0.055--1.620) Central1.606 (0.326--7.924)1.051 (0.191--5.769)US-LNM0.340.131 No1 (Reference)1 (Reference) Yes1.786 (0.542--5.884)2.254 (0.786--6.467)US-BIRADS classification0.7240.24 41 (Reference)1 (Reference) 52.710 (0.227--32.330)0.325 (0.027--3.866) 60.979 (0.372--2.572)0.156 (0.012--2.103)Clinical stageClinical T stage＜0.0010.0070.0050.003 T11 (Reference)1 (Reference)1 (Reference)1 (Reference) T21.767 (0.346--5.032)1.975 (0.496--5.916)3.142 (0.580--17.024)2.251 (0.643--7.433) T31.432 (0.268--7.640)1.548 (0.231--6.300)1.946 (0.172--5.192)1.706 (0.300--4.660) T41.724 (0.106--4.904)1.363 (0.128--4.028)1.669 (0.090--4.993)1.630 (0.209--4.898)Clinical N stage0.2330.88 N01 (Reference)1 (Reference) N10.835 (0.124--5.623)0.914 (0.163--5.125) N21.071 (0.199--5.764)1.626 (0.250--10.576) N31.197 (0.178--8.061)1.541 (0.173--13.766)Clinical TNM stage0.0610.814 II1 (Reference)1 (Reference) III2.385 (1.070--8.390)2.206 (1.008--7.296)Neoadjuvant chemotherapy regimen0.0330.7570.754 AC/ACF1 (Reference)1 (Reference)1 (Reference) CT/ACT1.004 (0.595--4.115)1.791 (0.304--5.060)1.642 (0.183--14.717) AT1.691 (0.356--8.033)1.627 (0.288--8.527)1.493 (0.270--8.239) TP1.786 (0.953--4.026)1.617 (0.250--4.527)2.944 (0.564--15.376) Others1.193 (0.750--8.450)1.571 (0.160--5.037)1.054 (0.070--15.943)Neoadjuvant chemotherapy times0.3240.246 ＜61 (Reference)1 (Reference) ≥61.706 (0.590--4.937)2.180 (0.584--8.141)Response0.0670.631 CR1 (Reference)1 (Reference) PR1.553 (0.766--7.458)4.021 (0.193--83.616) SD1.775 (1.048--6.516)3.767 (0.140--101.307) PD1.681 (1.046--7.183)0.781 (0.007--90.182)Tumor size0.0540.0010.019≤2cm1 (Reference)1 (Reference)1 (Reference)＞2 and ＜5cm1.564 (0.565--4.478)1.072 (0.118--3.296)1.400 (0.187--3.855)≥5cm1.540 (0.109--3.679)1.094 (0.111--3.787)1.261 (0.190--3.757)Type of surgery0.9350.217 Mastectomy1 (Reference)1 (Reference)Breast-conserving surgery1.054 (0.302--3.680)2.321 (0.609--8.844)Miller and Payne grade＜0.001＜0.001＜0.001＜0.001 11 (Reference)1 (Reference)1 (Reference)1 (Reference) 20.104 (0.017--0.645)0.823 (0.305--2.221)0.197 (0.023--1.687)0.855 (0.284--2.574) 30.080 (0.010--0.610)0.674 (0.248--1.830)0.503 (0.062--4.082)0.706 (0.239--2.090) 40.000 (0.000--0.008)0.283 (0.074--1.083)0.001 (0.000--0.046)0.097 (0.024--0.390) 50.012 (0.000--0.396)0.825 (0.166--4.109)2.807 (0.076--104.171)0.609 (0.083--4.458)Histologic type0.2810.152 Ductal1 (Reference)1 (Reference) Lobular0.063 (0.002--2.122)3.017 (0.061--149.412) Others0.367 (0.009--14.164)0.015 (0.000--1.446)Histologic grade0.1530.382 I1 (Reference)1 (Reference) II1.237 (0.574--3.263)0.387 (0.043--3.492) III1.748 (0.275--5.030)0.744 (0.077--7.202)Pathological TNM classificationPathological T stage0.003＜0.001＜0.001＜0.001 Tis/T01 (Reference)1 (Reference)1 (Reference)1 (Reference) T11.072 (0.738--4.645)1.069 (0.693--3.609)1.797 (1.039--7.626)1.790 (0.935--6.917) T21.040 (0.130--3.025)1.671 (0.377--3.608)1.074 (0.382--4.624)1.988 (0.518--5.806) T31.338 (0.188--4.071)1.578 (0.371--5.072)1.435 (0.634--6.288)1.036 (0.867--3.487) T41.230 (0.211--5.113)1.536 (0.611--4.383)1.067 (0.913--4.864)1.357 (0.780--4.279)Pathological N stage0.0650.169 N01 (Reference)1 (Reference) N11.123 (0.115--3.265)1.633 (0.282--3.794) N21.921 (0.295--5.052)1.161 (0.872--3.325) N32.254 (0.645--7.540)1.705 (0.446--3.243)Pathological TNM stage＜0.001＜0.001＜0.001＜0.001 Tis/T01 (Reference)1 (Reference)1 (Reference)1 (Reference) I1.568 (0.949--3.986)1.789 (0.751--4.261)3.189 (1.275--7.973)2.829 (1.105--7.245) II1.180 (0.760--3.431)1.128 (0.482--2.642)1.121 (0.441--2.849)1.294 (0.491--3.407) III1.889 (0.930--4.383)1.871 (0.868--4.031)1.034 (0.385--2.776)1.475 (0.536--4.059)Total lymph nodes0.9950.939 ＜211 (Reference)1 (Reference) ≥211.007 (0.108--9.349)1.044 (0.345--3.164)Positive lymph nodes0.0050.0090.811 01 (Reference)1 (Reference)1 (Reference) ＜61.700 (0.000--3.539)3.789 (1.471--9.763)1.722 (0.049--60.858) ≥61.752 (0.000--4.224)6.037 (1.808--20.161)2.522 (0.115--55.522)Core needle biopsyMolecular subtype0.0110.0160.0120.01 Luminal A1 (Reference)1 (Reference)1 (Reference)1 (Reference) Luminal B HER2+1.023 (0.110--2.542)1.064 (0.117--2.595)1.826 (0.447--6.980)1.598 (0.610--5.907) Luminal B HER2-0.109 (0.006--1.964)0.435 (0.143--1.323)0.225 (0.005--10.031)0.657 (0.212--2.037) HER2 enriched1.384 (0.804--5.178)1.127 (0.714--3.172)1.245 (0.361--6.215)1.257 (0.126--5.562) Triple negative1.166 (0.676--5.757)1.638 (0.373--7.190)2.574 (0.402--9.387)1.932 (0.441--8.458)ER status＜0.001＜0.0010.0020.006 Negative1 (Reference)1 (Reference)1 (Reference)1 (Reference) Positive1.916 (0.617--4.906)1.688 (0.373--7.190)1.571 (0.993--3.167)1.281 (0.448--3.664)PR status0.3520.525 Negative1 (Reference)1 (Reference) Positive2.116 (0.437--10.256)1.879 (0.269--13.140)HER2 status0.5420.426 Negative (0\--++)1 (Reference)1 (Reference) Positive (+++)3.808 (1.052--9.730)2.396 (0.278--20.618)Ki-67 status0.0170.0010.005＜0.001 Negative (≤14%)1 (Reference)1 (Reference)1 (Reference)1 (Reference) Positive (＞14%)5.275 (1.346--20.674)2.230 (1.391--3.574)5.885 (1.037--33.391)2.558 (1.565--4.183) Postoperative pathology (IHC)Molecular subtype0.440.052 Luminal A1 (Reference)1 (Reference) Luminal B HER2+0.325 (0.007--14.229)0.001 (0.000--0.134) Luminal B HER2-0.775 (0.023--26.006)0.033 (0.001--1.878) HER2 enriched0.039 (0.000--6.483)0.000 (0.000--0.056) Triple negative0.042 (0.001--2.145)0.006 (0.000--1.097)ER status0.0250.9090.0360.478 Negative1 (Reference)1 (Reference)1 (Reference)1 (Reference) Positive0.142 (0.026--0.784)0.937 (0.306--2.867)0.131 (0.020--0.875)1.487 (0.497--4.445)PR status0.0250.0040.143 Negative1 (Reference)1 (Reference)1 (Reference) Positive6.341 (1.259--31.939)2.569 (1.356--4.870)4.265 (0.612--29.730)HER2 status0.1230.0010.348 Negative (0\--++)1 (Reference)1 (Reference)1 (Reference) Positive (+++)1.553 (0.446--6.299)1.053 (0.761--4.687)2.006 (0.469--8.583)Ki-67 status0.01＜0.0010.003＜0.001 Negative (≤14%)1 (Reference)1 (Reference)1 (Reference)1 (Reference) Positive (＞14%)5.267 (1.476--18.797)2.843 (1.639--4.932)4.634 (0.981--11.885)4.071 (2.252--7.358)AR status0.060.483 Negative1 (Reference)1 (Reference) Positive0.294 (0.082--1.052)0.657 (0.203--2.123)CK5/6 status0.0350.1230.804 Negative1 (Reference)1 (Reference)1 (Reference) Positive0.097 (0.011--0.847)0.509 (0.216--1.200)0.770 (0.098--6.076)E-cad status0.3130.214 Negative1 (Reference)1 (Reference) Positive0.567 (0.189--1.705)2.327 (0.615--8.812)EGFR status0.1490.081 Negative1 (Reference)1 (Reference) Positive0.399 (0.115--1.389)0.202 (0.034--1.218)P53 status0.7710.498 Negative1 (Reference)1 (Reference) Positive0.848 (0.280--2.566)1.521 (0.453--5.105)TOP2A status0.0160.1310.0020.207 Negative1 (Reference)1 (Reference)1 (Reference)1 (Reference) Positive0.250 (0.081--0.770)0.635 (0.352--11.145)0.094 (0.021--0.422)0.685 (0.381--1.233)Lymph vessel invasion0.010.0080.064 Negative1 (Reference)1 (Reference)1 (Reference) Positive4.720 (1.444--15.435)3.598 (1.783--13.263)3.474 (0.931--12.958)Neural invasion0.0350.0010.0170.028 Negative1 (Reference)1 (Reference)1 (Reference)1 (Reference) Positive4.512 (1.115--18.263)3.277 (1.127--9.602)1.481 (0.129--4.800)1.473 (0.211--4.053)CA1250.1870.279 ＜27.731 (Reference)1 (Reference) ≥27.732.355 (0.659--8.412)1.701 (0.368--5.334)CA1530.120.1500.835 ＜21.861 (Reference)1 (Reference)1 (Reference) ≥21.862.512 (0.785--8.036)1.819 (1.124--2.941)1.121 (0.383--3.283)CEA0.8230.184 ＜3.521 (Reference)1 (Reference) ≥3.521.125 (0.400--3.164)2.356 (0.666--8.340)White blood cell (W)0.1420.928 ＜6.001 (Reference)1 (Reference) ≥6.002.966 (0.696--12.644)0.936 (0.221--3.971)Red blood cell (R)0.7230.914 ＜4.341 (Reference)1 (Reference) ≥4.341.185 (0.463--3.035)1.060 (0.367--3.062)Hemoglobin (Hb)0.0820.424 ＜128.001 (Reference)1 (Reference) ≥128.002.716 (0.881--8.377)1.678 (0.471--5.970)Neutrophil (N)0.7830.109 ＜3.831 (Reference)1 (Reference) ≥3.831.246 (0.261--5.947)5.384 (0.687--42.223)Lymphocyte (L)0.9570.291 ＜1.671 (Reference)1 (Reference) ≥1.671.041 (0.241--4.502)2.246 (0.501--10.069)Monocyte (M)0.5330.242 ＜0.341 (Reference)1 (Reference) ≥0.341.425 (0.467--4.347)0.527 (0.180--1.542)Platelet (P)0.1790.375 ＜244.001 (Reference)1 (Reference) ≥244.000.527 (0.207--1.343)0.586 (0.179--1.911)NLR0.1630.932 ＜2.501 (Reference)1 (Reference) ≥2.502.214 (0.725--6.762)1.051 (0.336--3.288)MLR0.6060.685 ＜0.221 (Reference)1 (Reference) ≥0.221.395 (0.395--4.929)0.755 (0.194--2.934)PLR0.0010.0090.0010.004 ＜160.001 (Reference)1 (Reference)1 (Reference)1 (Reference) ≥160.007.254 (2.297--22.908)3.601 (1.930--10.756)1.704 (0.921--3.005)2.014 (1.154--3.516)SIRI0.0180.0110.0070.002 ＜0.851 (Reference)1 (Reference)1 (Reference)1 (Reference) ≥0.851.817 (0.389--8.485)1.694 (1.128--2.543)1.321 (1.049--4.109)1.288 (0.781--3.124)Postoperative chemotherapy0.0030.0110.020.017 No1 (Reference)1 (Reference)1 (Reference)1 (Reference) Yes5.903 (1.811--19.236)1.836 (1.152--2.928)4.503 (1.263--16.059)3.001 (1.068--10.764)Postoperative radiotherapy0.0030.0020.0010.003 No1 (Reference)1 (Reference)1 (Reference)1 (Reference) Yes0.300 (0.045--1.099)0.596 (0.304--1.168)0.122 (0.036--0.410)0.513 (0.252--1.045)Postoperative endocrine therapy0.2230.76 No1 (Reference)1 (Reference) Yes1.942 (0.667--5.651)1.207 (0.362--4.019)Postoperative targeted therapy0.2990.967 No1 (Reference)1 (Reference) Yes1.953 (0.552--6.914)0.966 (0.193--4.832) Figure 1DFS and OS of patients with breast cancer. (**A**) Kaplan--Meier analysis of DFS of all patients with breast cancer. (**B**) Kaplan--Meier analysis of OS of all patients with breast cancer. (**C**) Kaplan--Meier analysis of DFS for the SIRI of all patients with breast cancer. (**D**) Kaplan--Meier analysis of OS for the SIRI of all patients with breast cancer. SIRI is a novel systemic inflammation response index (SIRI=N×M/L), which is based on neutrophil (N), monocyte (M), and lymphocyte (L) counts.

The result was indicated that SIRI was the significant prognostic factor. And patients with low SIRI had significantly lower risks of disease progression compared with patients with high SIRI. Moreover, low SIRI was associated with prolonged DFS and OS by univariate analysis (P=0.018, hazard ratio \[HR\]: 1.817, 95% confidence interval \[CI\]: 0.389--8.485 and P=0.007, HR: 1.321, 95% CI: 1.049--4.109, respectively). And low SIRI was also associated with prolonged DFS and OS (P=0.011, HR: 1.694, 95% CI: 1.128--2.543 and P=0.002, HR: 1.288, 95% CI: 0.781--3.124, respectively; [Table 6](#T0006){ref-type="table"}).

In low SIRI group, the mean DFS and OS for all enrolled patients were 41.27 months (range from 4.00 to 197.97 months) and 52.86 months (range from 5.93 to 250.97 months), respectively. In high SIRI group, the mean DFS and OS for all enrolled patients were 30.45 months (range from 4.93 to 194.90 months) and 45.75 months (range from 8.13 to 238.27 months), respectively. We also found that the mean DFS and OS time for patients with low SIRI were longer than for those with high SIRI by using log-rank methods (*χ*^2^=4.766, P=0.029 and *χ*^2^=4.181, P=0.041, respectively; [Figure 1C](#F0001){ref-type="fig"} and [D](#F0001){ref-type="fig"}).

Survival and Evaluation of the Prognostic Significance of SIRI {#S0003-S2007}
--------------------------------------------------------------

Among the 262 patients with breast cancer, the DFS rates at 3-, 5-, and 10-year were 31.7% (83/262), 17.2% (45/262), 4.6% (12/262); the OS rates at 3-, 5-, and 10-year were 42.7% (112/262), 28.2% (74/262), 7.6% (20/262), respectively. In low SIRI group, the DFS rates at 3-, 5-, and 10-year were 36.1% (56/155), 20.6% (32/155), 5.8% (9/155); and the OS rates at 3-, 5-, and 10-year in low SIRI were 46.5% (72/155), 31.0% (48/155), 8.4% (13/155), respectively. In high SIRI group, the DFS rates at 3-, 5-, and 10-year were 25.2% (27/107), 12.1% (13/107), 2.8% (3/107), respectively. The results were indicated that patients in low SIRI group had better 3-, 5-, and 10-year rates of DFS and OS than those in high SIRI group. However, there were no significant differences between low SIRI group and high SIRI group among 3-, 5-, and 10-year rates ([Table 7](#T0007){ref-type="table"}, [Figure 2A](#F0002){ref-type="fig"}--[D](#T0007){ref-type="table"}).Table 73-, 5-, and 10-Year DFS and OS Rates of Breast Cancer PatientsParametersCases (n)DFSOS3 Years (%)5 Years (%)10 Years (%)3 Years (%)5 Years (%)10 Years (%)Total26283/262 (31.7%)45/262 (17.2%)12/262 (4.6%)112/262 (42.7%)74/262 (28.2%)20/262 (7.6%)Low SIRI15556/155 (36.1%)32/155 (20.6%)9/155 (5.8%)72/155 (46.5%)48/155 (31.0%)13/155 (8.4%)High SIRI10727/107 (25.2%)13/107 (12.1%)3/107 (2.8%)40/107 (37.2%)26/107 (24.3%)7/107 (6.5%)*χ*^2^3.4723.2121.3062.1271.3890.306P value0.0620.0730.2530.1440.2390.58 Figure 2The 3-, 5-, and 10-year rates of DFS and OS in patients with breast cancer. (**A**) The 3-, 5-, and 10-year rates of DFS in all patients with breast cancer. (**B**) The 3-, 5-, and 10-year rates of OS in all patients with breast cancer. (**C**) The 3-, 5-, and 10-year rates of DFS in all patients by SIRI with breast cancer. (**D**) The 3-, 5-, and 10-year rates of OS in all patients by SIRI with breast cancer.

Association of Molecular Subtypes by Core Needle Biopsy and SIRI in Patients with Breast Cancer {#S0003-S2008}
-----------------------------------------------------------------------------------------------

By univariate and multivariate analysis, the molecular subtypes by core needle biopsy was the significant prognostic factor in [Table 6](#T0006){ref-type="table"}. In order to further evaluate the prognostic value of SIRI, the SIRI was accessed by the molecular subtypes. The SIRI with different molecular subtypes was analyzed by the log-rank test. And the patients with low SIRI had longer DFS and OS than those with high SIRI. Moreover, the mean DFS and OS time for patients with low SIRI by the log-rank test were longer than in those with high SIRI in HER2-positive subtype (*χ*^2^=5.349, P=0.021 and *χ*^2^=3.277, P=0.070, respectively). However, there were no significant differences between low SIRI group and high SIRI group by other molecular subtypes.

Correlation Between Miller and Payne Grade (MPG) and SIRI in Patients with Breast Cancer {#S0003-S2009}
----------------------------------------------------------------------------------------

According to univariate and multivariate analyses, the MPG was the significant prognostic factor ([Table 6](#T0006){ref-type="table"}). In order to further evaluate the prognostic efficiency of SIRI, we analyzed the SIRI by MPG. The SIRI with different MPG Grade was analyzed by the log-rank test. The mean DFS and OS time for patients with low SIRI were longer than in those with high SIRI. However, there were no significant differences between low SIRI group and high SIRI group by MPG.

Association of Pathological TNM Stage and SIRI in Patients with Breast Cancer {#S0003-S2010}
-----------------------------------------------------------------------------

According to univariate and multivariate analyses, pathological TNM stage was the significant prognostic factor. Hence, in order to further to study the prognostic efficiency of SIRI, the SIRI was analyzed by pathological TNM stage. The SIRI with different pathological TNM stage was analyzed by the log-rank test. The mean DFS and OS time for patients with low SIRI were longer than in those with high SIRI. However, there were no significant differences between low SIRI group and high SIRI group by pathological TNM stage.

Correlation Between Ki-67 Status and SIRI in Patients with Breast Cancer {#S0003-S2011}
------------------------------------------------------------------------

The results indicated that Ki-67 status in both core needle biopsy and postoperative pathology IHC was the significant prognostic factor. In core needle biopsy, the mean DFS and OS time for patients with low SIRI by the log-rank test were longer than in those with high SIRI in Ki-67 negative (*χ*^2^=3.195, P=0.074 and *χ*^2^=1.393, P=0.238, respectively). Moreover, the mean DFS and OS time for patients with low SIRI by the log-rank test were longer than in those with high SIRI in Ki-67 positive (*χ*^2^=1.730, P=0.189 and *χ*^2^=5.028, P=0.025, respectively). In postoperative pathology IHC, the mean DFS and OS time for patients with low SIRI by the Log-rank test were longer than in those with high SIRI in Ki-67 negative (*χ*^2^=5.451, P=0.020 and *χ*^2^=3.360, P=0.067, respectively). And the mean DFS and OS time for patients with low SIRI by the log-rank test were longer than in those with high SIRI in Ki-67 positive (*χ*^2^=0.564, P=0.453 and *χ*^2^=2.088, P=0.149, respectively).

Association of Neural Invasion and SIRI in Patients with Breast Cancer {#S0003-S2012}
----------------------------------------------------------------------

The neural invasion was the significant prognostic factor by univariate and multivariate analyses in [Table 6](#T0006){ref-type="table"}. Consequently, in order to further determine the prognostic efficiency of SIRI, the SIRI was analyzed by neural invasion. The results proved that the mean DFS and OS time for patients with low SIRI by the log-rank test were longer than in those with high SIRI in patients without lymph vessel invasion (*χ*^2^=8.290, P=0.004 and *χ*^2^=7.209, P=0.007, respectively). And the results show that the mean DFS and OS time for patients with low SIRI by the log-rank test were longer than in those with high SIRI in patients with neural invasion (*χ*^2^=0.051, P=0.822 and *χ*^2^=0.016, P=0.901, respectively).

Discussion {#S0004}
==========

Breast cancer is the most common women cancer and is the major leading cause of cancer-related death all over the world.[@CIT0024] Comprehensive therapies, including operation, chemotherapy, radiotherapy, endocrine therapy, and targeted therapy, have improved survival time and quality of life for these breast cancer patients.[@CIT0025] The neoadjuvant treatment can turn inoperable tumors into operable tumors or reduce tumor stage for more frequent conservative breast surgery. Moreover, NACT has become the standard treatment for locally advanced breast cancer, and the quality of life and clinical outcomes for these patients have largely improved.[@CIT0026] Therefore, it is of importance to search accurate indicator for choosing the optimal treatment regimen and improving clinical outcomes.

Various studies have shown that tumors are associated to systemic inflammation.[@CIT0027]--[@CIT0029] However, the mechanisms between tumors and inflammation reaction are yet ambiguous and poorly understood. Some studies have suggested that systemic inflammatory cells, such as neutrophils, monocytes, platelets, and lymphocytes, are linked to prognosis of many malignancies. Neutrophils restrain inflammatory factors, which include matrix metalloproteinase-9 (MMP-9), nuclear factor-κB (NF-kB) and vascular endothelial growth factor (VEGF), to influence the proliferation, development, progression, and metastasis.[@CIT0030]--[@CIT0032] Monocytes have been proved that it can promote tumor angiogenesis, inflammatory response and metastases, and releases some cytokines and chemokines, such as oncostatin-M and VEGF, to inhibit the immune system.[@CIT0033],[@CIT0034] Platelets are an indicator of tumor activity and angiogenesis, and are associated with tumor growth, invasion, and metastasis by releasing VEGF-integrin cooperative signaling.[@CIT0035],[@CIT0036] Moreover, lymphocytes are an important component of anticancer immunity and immune surveillance and are associated to prevent the tumor growth and progression.[@CIT0037],[@CIT0038]

Some studies have shown that inflammatory markers and immune-based prognostic indexes were used to evaluate the prognosis of breast cancer, such as NLR, d-NLR, MLR/LMR, and PLR.[@CIT0039]--[@CIT0041] However, these inflammatory markers were associated with poor prognosis in breast cancer patients, and the potential mechanisms were not yet clear. The SIRI based on three inflammatory cells, such as neutrophil, monocyte, and lymphocyte, and can fully evaluate the balance between host immune and inflammatory condition. Nevertheless, the prognostic value of the preoperative SIRI in breast cancer patients received NACT is still unclear. In the present study, the SIRI was the significant prognostic factor by univariate and multivariate analyses.

In our study, the clinicopathologic and demographic characteristics of all enrolled patients were analyzed. The optimal cutoff value of the SIRI was 0.85×10^9^/L by ROC analysis. The results shown that low SIRI was significantly associated with menopause, US-LNM and total lymph nodes. And the low SIRI was in connection with W, Hb, N, L, M, NLR, MLR, and PLR. Moreover, the low SIRI was also significantly associated with NACT. Meanwhile, the common toxicities after NACT were hematologic and gastrointestinal reaction, and the SIRI had no significance on toxicities of all enrolled patients, excepted diarrhea.

On the basis of univariate and multivariate Cox regression analyses, the clinical T stage, Miller and Payne grade, pathological T stage, pathological TNM stage, core needle biopsy (molecular subtype, ER status, Ki-67 status), postoperative pathology IHC (Ki-67 status), neural invasion, PLR, SIRI, postoperative chemotherapy, postoperative radiotherapy were the independent factors. We also found that patients with low SIRI had better prognosis and survived longer than those with high SIRI. Meanwhile, patients with low SIRI had higher 3-, 5-, and 10-year rates. Moreover, our results indicated that Ki-67 status was the significant prognostic factor, and patients with low SIRI had better prognosis and survived longer than those with high SIRI. The results also indicated that patients with low SIRI had better prognosis than those with high SIRI in patients with neural invasion.

Several limitations are presented in this study. Firstly, this is a retrospective single-center study. And multicenter study and more patients should be enrolled. Secondly, the cases are not more by subgroup analysis, and influence the outcomes. Thirdly, the SIRI value of different studies may be different by different cutoff points or endpoints. Therefore, more and better designed randomized controlled trials should be studied to support our findings, and further to study the SIRI and try to combine with other biomarkers to access the clinical outcome.

Conclusion {#S0005}
==========

SIRI is the significant prognostic factor for breast cancer patients and can effectively predict the survival and prognosis for breast cancer. Taking into consideration the high incidence of breast cancer and the unbalanced distribution of medical conditions in China, the repeatable, convenient and non-invasive biomarkers should be used in the prevention and treatment of breast cancer. A comprehensive understanding of hematological parameters is of great importance for finding new targets for subjective treatment and doctors to implement effective treatment in clinical practice.
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